Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EVMN
EVOMMUNE, INC.
NYSE
$13.08
▲ UP 6.60% (0.81)

KEY STATISTICS

Market Cap$477.24 M
52w High$33.20
52w Low$10.47
Dividend Yield—
Frequency—
P/E-1.29
Volume1.04M
Shares Out.36.29M

COMPANY

LEADERSHIP

Luis C. Pena
CHIEF EXECUTIVE
Luis C. Pena

COMPENSATION 2026

Salary$588,462
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$11,022,670

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 6, 2025
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
48

PRICE TARGET

Target High$50.00
Target Low$26.00
Target Median$38.00
Target Consensus$38.00

UPCOMING EARNINGS

DateOct 16, 2026
DayFriday
Rev. Est.$500.00K
OCT
16
FRI

PRICE

$13.08 ▲ UP 6.60% (+$0.81)
$12.00$12.40$12.80$13.209:33 AM10:37 AM11:42 AM12:46 PM1:50 PM2:55 PM3:59 PM13.08

About Evommune, Inc.

https://www.evommune.com ↗

Evommune, Inc., a clinical-stage biotech founded in 2020 in Palo Alto, develops therapies targeting chronic inflammatory diseases like CSU, atopic dermatitis, and ulcerative colitis, including EVO756 and EVO301.

INDUSTRY

Biotechnology

A PRODUCT EVOMMUNE, INC. IS KNOWN FOR

EVO301
EVO301

EVO301 is a clinical-stage long-acting injectable fusion protein for moderate-to-severe atopic dermatitis, becoming Evommune's leading candidate after positive Phase 2a results in February 2026.

COMPETITORS

COMPETITOR
APGE COMPARE
INCY COMPARE
KYMR COMPARE
NKTR COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
58
LISTED HERE
15
RANKED BY POSITION SIZE
VTS.AX
0.00% · 739.1K
IWM
0.00% · 326.9K
FESM
0.03% · 145.0K
SCHA
0.00% · 52.9K
SBIO
0.24% · 49.6K
R2SC.L
0.01% · 27.6K
BBC
0.37% · 15.8K
XRSG.L
0.00% · 11.1K
AVSC
0.00% · 8.0K
ACSG
0.15% · 6.6K
RSSL
0.01% · 6.0K
TILT
0.00% · 2.5K
URTY
0.00% · 497
RESM
0.01% · 39
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
61.20%
HOLDERS
84
TOP 12 OF 84 · RANKED BY POSITION SIZE
Eqt Fund Management S.A R.L.
4.9M sh · $113.33M
Ra Capital Management, L.P.
3.5M sh · $80.34M
Pivotal Bioventure Partners Investment Advisor LLC
1.9M sh · $44.3M
Andera Partners
1.9M sh · $43.62M
Rtw Investments, LP
1.5M sh · $34.54M
Jpmorgan Chase & Co
1.5M sh · $32.11M
Bioimpact Capital LLC
1.5M sh · $33.47M
Nan Fung Group Holdings Ltd
1.4M sh · $33.13M
Eventide Asset Management, LLC
1.2M sh · $27.8M
Price T Rowe Associates Inc /Md/
1.1M sh · $25.73M
Janus Henderson Group Plc
896.7K sh · $20.62M
Marshall Wace, Llp
879.7K sh · $20.22M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
NEUTRAL 1
OVERWEIGHT 1
MARKET PERFORM 1
4 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM HC Wainwright & Co. NEUTRAL Morgan Stanley OVERWEIGHT William Blair MARKET PERFORM

SECTORS PEERS

PEERPRICE
LGND$284.19COMPARE
ZYME$28.68COMPARE
FTRE$17.59COMPARE
CLYM$15.83COMPARE
OABI$4.21COMPARE
ARTV$10.89COMPARE
EYPT$4.56COMPARE
CDXS$1.47COMPARE